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Abstract
Introduction Dalbavancin is a new lipoglycopeptide that
is active against Gram-positive pathogens, including
methicillin-resistant Staphylococcus aureus. It has a half-
life of 14.4 days, permitting intravenous treatment of acute
bacterial skin and skin structure infections without the need
for daily dosing.
Objective The objective of these analyses was to compare
the adverse event profile of dalbavancin with that of the
comparator agents in the treatment of skin and skin struc-
ture infections.
Methods Data on adverse events and laboratory assess-
ments collected from 3002 patients enrolled in seven late-
stage, randomized clinical trials were analyzed for patients
receiving dalbavancin or a comparator antibiotic.
Results Overall adverse event rates were similar or lower
for patients receiving dalbavancin (799/1778; 44.9 %)
compared with those receiving comparator agents (573/
1224; 46.8 %, p = 0.012). The most common treatment-
emergent adverse events were nausea, headache, diarrhea,
constipation, vomiting, rash, urinary tract infection, pruri-
tus, and insomnia. The duration and timing of the onset of
adverse events were similar for patients receiving dalba-
vancin relative to the comparators.
Conclusion Dalbavancin exhibits a favorable overall
safety profile for treatment of acute bacterial skin and skin
structure infections due to Gram-positive bacteria.
Key Points
Treatment with dalbavancin was well tolerated.
The long half-life of dalbavancin did not lead to any
safety concerns.
1 Introduction
Over the last decade, the USA has witnessed a dramatic
increase in the incidence of community-acquired skin
infections, an increasing proportion of which are a conse-
quence of methicillin-resistant Staphylococcus aureus
(MRSA), reinforcing the need for new and effective
antibacterial therapies in this disease [1–4]. Dalbavancin is
a lipoglycopeptide with activity against Gram-positive
organisms, including MRSA, through interference with
bacterial cell wall formation by preventing cross-linking of
peptidoglycans. Dalbavancin has a distinctive pharma-
cokinetic profile, with a terminal half-life of 14.4 days,
which allows for infrequent intravenous dosing. It is not
metabolized, does not interact with cytochrome P450
enzymes, and is eliminated via both hepatic and renal
routes [5]. After entering human studies in 2003, dalba-
vancin has been studied in 14 phase I, two phase II, and
five phase III studies [5–11]. Presented here are safety data
& Michael W. Dunne
michael.w.dunne@comcast.net
1 Durata Therapeutics, Inc., 322 East Main Street, Branford,
CT 06405, USA
2 Talbot Advisors, LLC, Anna Maria, FL, USA
3 Division of Infectious Diseases and Geographic Medicine,
Tufts Medical Center, Tufts University School of Medicine,
Boston, MA, USA
4 Microbiology, Leeds Teaching Hospital, Leeds, UK
5 Old Medical School, University of Leeds, Leeds, UK
Drug Saf (2016) 39:147–157
DOI 10.1007/s40264-015-0374-9
from patients enrolled in all seven phase II and phase III
studies in the dalbavancin clinical development program
that lead to US and European regulatory approval for the
treatment of acute bacterial skin and skin structure infec-
tions (ABSSSI) [12, 13].
2 Methods
2.1 Studies
The dalbavancin clinical development program was con-
ducted between 2002 and 2013. All phase II and phase III
clinical trials for the treatment of uncomplicated and
complicated skin infection, catheter-related bloodstream
infection and ABSSSI supported by the sponsor and sub-
mitted to the regulatory authorities for review and mar-
keting approval are included in the analyses (Table 1). As
dalbavancin was not available commercially prior to 2013,
these studies represent all clinical trials performed to date.
All studies were randomized controlled trials comparing
dalbavancin with a comparator agent and were designed as
non-inferiority trials. The protocols for all studies were
reviewed by the local ethics committees of participating
institutions and were consistent with the Declaration of
Helsinki. All patients provided written informed consent.
Dalbavancin was delivered intravenously over 30 min
as 1000 mg on day 1 and 500 mg on day 8. In VER001-8
and VER001-16, a total of 273 and 49 patients, respec-
tively, with uncomplicated skin infection were given the
option of stopping after the first 1000-mg dose. In
VER001-5, a total of 20 patients received a single 1100-mg
dose. No adjustment for weight or body mass index (BMI)
was required in the clinical program. Comparator agents
included vancomycin, linezolid, cefazolin, nafcillin, or
oxacillin. Follow-up was performed through day 28 in all
studies except the two pivotal studies for ABSSSI (DIS-
COVER 1 and DISCOVER 2), where the last follow-up
visit occurred at day 70.
2.2 Data
All patients in the phase II and phase III studies presented
with an infection of the skin or, in one phase II study, a
catheter-related bloodstream infection, and are included in
the safety analyses. Safety data were collected carefully
during each clinical trial. Each protocol outlined the
requirements for reporting of adverse events, but, briefly,
all observed or volunteered adverse events, regardless of
treatment group or suspected causal relationship to study
drug, were reported from the time that the patient provided
informed consent through the last follow-up visit. Adverse
Table 1 Treatment-related
adverse events in randomized




N Two dosesa One doseb N Regimen
All phase II/III studies 1778 1428 350 1224
Phase II studies 81 54 27 55
Catheter-related bloodstream infections
VER001-4 [11] 40 34 6 34 Vancomycin
Skin and skin structure infections
VER001-5 [9] 41 20 21c 21 Standard of care
Phase III studies 1697 1374 323 1169
Uncomplicated skin and skin structure infection
VER001-8 (Data on file, Allergan
plc.) [16]
367 94 273 186 Cefazolin
Complicated skin and skin structure infection
VER001-16 (Data on file, Allergan
plc.) [16]
107 57 50 49 Vancomycin
VER001-9 [8] 571 571 0 283 Linezolid
Acute bacterial skin and skin structure infection
DUR001-301 (DISCOVER 1) [10] 284 284 0 284 Vancomycin/linezolid
DUR001-302 (DISCOVER 2) [10] 368 368 0 367 Vancomycin/linezolid
Comparator agents include cephalosporins, vancomycin, oxacillin, nafcillin and linezolid. Studies
VER001-4, 5, and 16 were open-label trials; all others were double blinded. DISCOVER 1 and DISCOVER
2 ClinicalTrials.gov numbers, NCT01339091 and NCT01431339
a Intravenous dalbavancin 1000 mg on day 1 followed by 500 mg on day 8
b Intravenous dalbavancin 1000 mg on day 1
c Intravenous dalbavancin 1100 mg
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events included clinically significant symptoms and signs,
changes in physical examination findings, hypersensitivity,
and progression or worsening of underlying disease.
Severity was assessed as mild, moderate, or severe based
on the investigator’s clinical impression rather than a result
of specific criteria for defining the severity of an event.
Causality was determined by the investigator for all
adverse events as unrelated, unlikely related, possibly
related, or probably related to the study drug. Serious
adverse events are those that result in death, are life-
threatening, require inpatient hospitalization or prolonga-
tion of existing hospitalization, result in persistent or sig-
nificant disability or incapacity, result in congenital
anomaly or birth defect, or are assessed as being a medi-
cally important event based on medical and scientific
judgment. The timing of laboratory assessments, including
hematology and biochemistry parameters, was defined in
each protocol and performed at baseline and at periodic
intervals, including days 3, 8, 14, or 28.
2.3 Statistics
In all safety analyses, data are pooled at the patient level
across studies, as is typical for the purposes of reporting
safety data to regulatory authorities and in retrospective
reviews of adverse drug reactions [14, 15]. The safety
analyses included patients who were randomized and
received a dose of study drug in all the phase II or phase III
clinical trials completed through 2013. Patients received
the two-dose regimen of dalbavancin or, where permitted
in protocols enrolling patients with uncomplicated skin
infections, a single 1000-mg dose. For all analyses of
treatment-emergent adverse events (TEAEs), if the same
adverse event was reported for the same patient more than
once, the adverse event was counted only once for that
preferred term and at the highest intensity and strongest
relationship to study drug. Differences between treatment
groups were analyzed using Fisher’s exact test for
dichotomous variables (sex, ethnicity, race) and the Wil-
coxon rank-sum test for continuous variables (age, BMI,
creatinine clearance), prospectively for patient demo-
graphics and post hoc, as relevant, for other analyses of
interest. Total adverse event comparisons were analyzed
using a Cochran–Mantel–Haenszel analysis to adjust for
study and a log-normal, Poisson regression model adjusted
by study on total number of treatment-related adverse
events per patient. No adjustments were made for multiple
comparisons, and p values are presented for descriptive
purposes only. Safety outcomes are presented as verbatim
descriptions of adverse events and were coded using Ver-
sion 14 or higher of MedDRA. All statistical analyses
were performed using SAS version 9.2.
3 Results
A total of 1778 patients enrolled in the phase II/III program
were randomized and treated with dalbavancin, and 1224
received a comparator agent (Fig. 1, Tables 1 and 2). The
median age of all patients receiving dalbavancin was 47.0
years, 17.6 % of patients were aged[65 years, 78 % were
White, 64.3 % were from North America, and 71.6 % of
3442 randomized
2092 on dalbavancin 1350 on comparator













7 did not receive study drug
2 did not receive study drug
652 received study drug
7 did not receive study drug
652 received study drug
Fig. 1 Flow chart of patients included in safety and efficacy analyses. ABSSSI acute bacterial skin and skin structure infection, cSSSI
complicated skin and skin structure infection, d/c patients discontinued from the study, uSSSI uncomplicated skin and skin structure infection
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patients exceeded a BMI of 25 kg/m2. Demographics were
similar in the comparator groups. Small differences
between treatment groups were observed in the distribution
of race and location and type of infection.
Approximately 85 % of patients completed the study
drug course of therapy, with the most commonly identified
reasons for discontinuation of study medication similarly
distributed among worsening clinical status, lost to follow-
up, an adverse event, and withdrawal of consent. A total of
89 % of patients completed the study; the most common
reasons for not completing the study included withdrawal
of consent, death, and lost to follow-up (Table 3).
Table 2 Demographics of











Min; max 16; 93 18; 92
Age distribution (years)
\65 1465 (82.4) 995 (81.3)
C65 313 (17.6) 229 (18.7)
Sex
Male 1066 (60.0) 711 (58.1)
Female 712 (40.0) 513 (41.9)
Race
Whitea 1388 (78.1) 1008 (82.4)
Black or African American 143 (8.0) 88 (7.2)
Asiana 36 (2.0) 41 (3.3)
American Indian or Alaska Native 5 (0.3) 4 (0.3)
Native Hawaiian or other Pacific Islander 1 (0.1) 1 (0.1)
Othera 205 (11.5) 82 (6.7)





Min; max 14; 98 14; 91
Body mass index distribution (kg/m2)
\18.5 23 (1.3) 18 (1.5)
18.5 to\25 465 (26.2) 359 (29.3)
C25 1273 (71.6) 841 (68.7)
Unknown 17 (1.0) 6 (0.5)
Indication
cSSSI/ABSSSIa 1294 (72.8) 973 (79.5)
uSSSIa 444 (25.0) 217 (17.7)
Catheter-related bloodstream infections 40 (2.2) 34 (2.8)
Locationa
North America 1143 (64.3) 689 (56.3)
Eastern Europe and South Africa 395 (22.2) 389 (31.8)
Western Europe 216 (12.1) 118 (9.6)
Asia–Pacific 24 (1.3) 28 (2.3)
Temperature C38 C at baselineb, n/N (%) 549/649 (84.6) 552/649 (85.0)
Median (range)a infection area (cm2) 324 (26–5100) 367 (72–3922)
Data are presented as N (%) unless otherwise indicated
ABSSSI acute bacterial skin and skin structure infection, cSSSI complicated skin and skin structure infection, SD standard
deviation, uSSSI uncomplicated skin and skin structure infection
a Comparisons with p\ 0.05 by Fisher’s exact test
b Among patients in the ABSSSI studies
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Death was infrequent for either dalbavancin or the com-
parator regimens (0.6 vs. 1.1 %, respectively). Relative to
those treated with comparator, patients receiving dalbavancin
experienced fewer TEAEs (44.9 vs. 46.8 %, respectively,
p = 0.012), fewer treatment-related adverse events (18.4 vs.
20.1 %, respectively, p = 0.014), and fewer treatment-re-
lated serious adverse events (0.2 vs. 0.7 %, respectively,
p = 0.021). Of the total number of adverse events, including
serious adverse events, fewer were judged by the investigator
as likely to be related todalbavancin relative to the comparator
(Table 4). The distribution of mild, moderate, and severe
events was similar for each regimen.
Treatment-related serious adverse events occurring in
patients treated with dalbavancin included progression of
Table 3 Disposition of patients
in phase II/III clinical
development program
Dalbavancin Comparator
Total treated 1778 1224
Completed study medication 1518 (85.0) 1061 (86.5)
Did not complete study medication 219 (12.3) 143 (11.7)
Treatment failure/worsening clinical status 25 (1.4) 16 (1.3)
Adverse event 49 (2.7) 31 (2.5)
Patient withdrew consent or for reason other than adverse event 21 (1.2) 19 (1.5)
Death 0 (0.0) 1 (0.1)
Patient lost to follow-up 27 (1.5) 13 (1.1)
Patient non-compliance 10 (0.6) 9 (0.7)
Withdrawn at investigator’s discretion 6 (0.3) 9 (0.7)
Other 81 (4.5) 45 (3.7)
Completed study 1595 (89.4) 1098 (89.6)
Did not complete study 190 (10.6) 127 (10.4)
Adverse event 0 (0.0) 1 (0.1)
Patient withdrew consent 42 (2.4) 22 (1.8)
Death 10 (0.6) 13 (1.1)
Patient lost to follow-up 107 (6.0) 67 (5.5)
Subject noncompliance 2 (0.1) 0 (0.0)
Prohibited concomitant medication used 1 (0.1) 0 (0.0)
Other 28 (1.6) 24 (2.0)
Data are presented as N (%)
Table 4 Adverse events in phase II/III clinical development program
Dalbavancin (N = 1778) Comparator (N = 1224) p value
Patients with the AE
TEAEa 799 (44.9) 573 (46.8) 0.012
Treatment-related TEAEa 328 (18.4) 246 (20.1) 0.014
Serious AEs 109 (6.1) 80 (6.5) 0.266
Serious treatment-related AEs 3 (0.2) 9 (0.7) 0.021
Discontinuation due to a TEAEa 53 (3.0) 35 (2.9) 0.857
Discontinuation due to a serious TEAEa 22 (1.2) 13 (1.1) 0.660
Death 10 (0.6) 14 (1.1) 0.087
Number of AEs
AEs, N (N/patient) 2386 (1.34) 1739 (1.42)
Treatment-related AEsb (N, % of total) 566 (23.7) 459 (26.4) 0.0004
Serious AEs (N, % of total) 135 (5.7) 100 (5.8) NS
Serious treatment-related AEsc (N, % of total) 3 (0.1) 9 (0.5) 0.036
Data are presented as N (%) unless otherwise indicated
AE adverse event, NS not significant, TEAE treatment-emergent adverse event
a Cochran–Mantel–Haenszel analysis, adjusted for study
b Log-normal, Poisson regression model adjusted by study on total number of treatment-related adverse events per patient
c Fisher’s exact test
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cellulitis, asymptomatic leukopenia in a patient with a
baseline white blood cell count of 6.9 9 103 cells/mm3 and
a nadir of 3.79 9 103 cells/mm3 that recovered to baseline
by day 29, and an anaphylactoid reaction (Table 5). The
patient with an anaphylactoid reaction was a 22-year-old
White male with a history of reactive airway disease and
atopy, who had received general anesthetic agents *3 h
earlier and aztreonam intravenously as a bolus immediately
prior to treatment with one dose of intravenous dalba-
vancin. After 15 min of a 30-min infusion, he developed
dyspnea, laryngospasm, and a decrease in blood pressure.
The dalbavancin infusion was stopped, and he was treated
immediately with epinephrine, midazolam, antihistamines,
and a 5-day course of prednisone. Symptoms and signs
associated with the event were considered to be completely
resolved within 1 h of discontinuation of the infusion and
did not recur.
Themost common adverse events with onset after starting
study drug treatment were nausea, headache, diarrhea, con-
stipation, vomiting, rash, urinary tract infection, pruritus,
and insomnia (Table 6). Nausea, diarrhea, and pruritus were
the most common treatment-related adverse events, with an
incidence of approximately C2 %. The duration of adverse
events was similar for dalbavancin and the comparator reg-
imens, with a median of 3.0 and 4.0 days and a mean of 7.7
and 8.0 days, respectively (Fig. 2). Additionally, the mean,
median, and range of the time to the onset of adverse events
were similar on each regimen (Fig. 3). An increase of
adverse events was observed at day 8, seen with both the
comparator and dalbavancin; this is most likely because the
protocols required a visit on day 8 and not necessarily
on days 4–7, allowing for a greater opportunity to report an
event on that day.
Adverse event rates with dalbavancin or comparator
were similar when assessed by age, sex, or race, as were
those related to impaired renal or hepatic function
(Table 7). Similar numbers of patients experienced an
infusion-related adverse event; however, given that dalba-
vancin is dosed only on day 1 and day 8, restricting the
reported adverse events to only those 2 days of active
dalbavancin infusion (i.e., not including placebo infusions
given on other days during the blinded clinical trials)
identified far fewer infusion-associated events in patients
treated with dalbavancin (12 events in 1778 patients vs. 53
events in 1224 comparator patients). Red man syndrome
was not identified in any patient receiving dalbavancin in
the phase II/III clinical program, although two such cases
were reported in phase I studies.
Laboratory assessments performed during the course of
the clinical trials demonstrated generally similar laboratory
changes post-baseline in patients treated with either dal-
bavancin or comparator (Table 8). No overall difference
was observed in the post-baseline measurements of alanine
transaminase (ALT) among patients enrolled in the phase II
or III studies, including subjects with an elevated ALT
measurement at baseline. Slightly more patients in the
dalbavancin treatment group with a normal ALT value at
baseline had a post-baseline ALT elevation greater than
three times the upper limit of normal (0.8 vs. 0.2 %
receiving dalbavancin and comparator, respectively), but
fewer patients had a similar degree of elevation if the ALT
was abnormal at baseline (12.7 vs. 14.2 % receiving dal-
bavancin and comparator, respectively). In eight of these
12 patients with a normal ALT at baseline, one or more
significant underlying hepatic disorders were identified,
such as hepatitis C, hepatitis B, acute cholecystitis, or
active alcohol abuse as measured by carbohydrate-deficient
Table 5 Treatment-related serious adverse events in phase II/III
clinical development program




Total 3 (0.2) 9 (0.7)
Leukopenia 1 (0.1) 0
Anaphylactoid reaction 1 (0.1) 0
Cellulitis 1 (0.1) 1 (0.1)
Renal failure acute 0 2 (0.2)
Gastrointestinal disorder 0 1 (0.1)
Face edema 0 1 (0.1)
Pancytopenia 0 1 (0.1)
Thrombocytopenia 0 1 (0.1)
Nephropathy toxic 0 1 (0.1)
Pancreatitis acute 0 1 (0.1)
Table 6 Treatment-emergent adverse events at [2 % in either





Treatment-emergent adverse events 799 (44.9) 573 (46.8)
Nausea 98 (5.5) 78 (6.4)
Headache 83 (4.7) 59 (4.8)
Diarrhea 79 (4.4) 72 (5.9)
Constipation 52 (2.9) 30 (2.5)
Vomiting 50 (2.8) 37 (3.0)
Rash 38 (2.1) 22 (1.8)
Urinary tract infection 36 (2.0) 16 (1.3)
Pruritus 32 (1.8) 35 (2.9)
Insomnia 27 (1.5) 30 (2.5)
Treatment-related and treatment-emergent adverse events
Nausea 49 (2.8) 40 (3.3)
Diarrhea 45 (2.5) 45 (3.7)
Pruritus* 11 (0.6) 23 (1.9)
* p = 0.001
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transferrin. No case met the criteria for Hy’s law. With
regard to renal function, an increase in creatinine was less
frequently observed in patients receiving dalbavancin, and
was most evident in subjects with a normal creatinine at
baseline.
Of special interest is a comparison of the rate of adverse
events in patients receiving the glycopeptide vancomycin
and the lipoglycopeptide dalbavancin. The DISCOVER
studies compared dalbavancin with vancomycin, with an
option to switch to oral linezolid to complete 10–14 days of
total therapy. In these two studies combined, 54 patients who
received vancomycin for at least 10 days were compared
with 637who received two doses of intravenous dalbavancin
and, to control for any demographic variables associated
with continuation of intravenous therapy only, 61 who
received dalbavancin and at least 10 days of intravenous
placebo (Table 9). Fewer TEAEs (p = 0.08) and serious
TEAEs (p = 0.03) were reported in patients treated with
dalbavancin. In an assessment of potential study drug impact
on renal function in this population, nephrotoxicity rates
were lower in patients receiving dalbavancin than in those
receiving vancomycin for at least 10 days [dalbavancin 3.3
vs. vancomycin 9.3 % (p = 0.06)], supported by rates of
nephrotoxicity in a smaller subset of patients, controlling for
factors related to continuation of intravenous therapy [dal-
bavancin 1.7 % vs. vancomycin 9.3 % (p = 0.21)].
4 Discussion
The safety of dalbavancin has been assessed in 14 clinical
studies, including seven phase II or phase III studies of skin
infection. The adverse event profile of dalbavancin has
been rigorously studied in these clinical trials, leading to
the regulatory approval for the indication of ABSSSI in the
USA and the EU. With a database of 1778 patients
receiving dalbavancin, it is possible to exclude with 95 %
confidence the occurrence of any as yet unobserved
Fig. 2 Duration of adverse
events
Fig. 3 Day of onset of adverse
events (AE). TEAE treatment-
emergent AE
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Table 7 Patients with adverse




Infusion-associated AEs 40/1778 (2.2) 38/1224 (3.1)
Number of infusion-associated events 48 55
Number of events on day of active infusion 12 53
Renal-associated AEs 33/1778 (1.9) 24/1224 (2.0)
Treatment-related renal-associated AEs 3 (0.2) 5 (0.4)
Serious renal-associated AEs 3 (0.2) 6 (0.5)
Treatment-related serious renal-associated AEs 0 3 (0.2)
Hepatobiliary AEs 19/1778 (1.1) 9/1224 (0.7)
Treatment-related treatment-emergent hepatobiliary AEs 6 (0.3) 1 (0.1)
Serious treatment-emergent hepatobiliary AEs
All treatment-emergent hepatobiliary AEs 3 (0.2) 2 (0.2)
Treatment-related hepatobiliary AEs 0 0
TEAE by age, sex, or race
\65 years of age 641/1465 (43.8) 465/995 (46.7)
C65 years of age 158/313 (50.5) 108/229 (47.2)
Male 449/1066 (42.1) 308/711 (43.3)
Female 350/712 (49.2) 265/513 (51.7)
White 579/1388 (41.7) 448/1008 (44.4)
Black 90/143 (62.9) 58/88 (65.9)
Other 130/247 (52.6) 67/127 (52.8)
Data are presented as n (%) or n/N (%) unless otherwise indicated
AE adverse event, TEAE treatment-emergent adverse event
Table 8 Selected laboratory
measurements (phase II/III
clinical development program)
Organ system Parameter Criteria, post-baseline Dalbavancin Comparator
Renal Creatinine C1.5 9 ULN and Ctwofold : 3 (0.2) 6 (0.6)
[ULN but normal at baseline* 51 (3.6) 63 (6.6)
[ULN but high at baseline 69 (46.3) 63 (52.5)
Hematologic Hematocrit B0.8 9 LLN and C0.25-fold ; 5 (0.3) 4 (0.4)
Platelets B0.6 9 LLN and C0.4-fold ; 2 (0.1) 4 (0.4)
WBC B0.5 9 LLN and C0.75-fold ; 1 (0.1) 1 (0.1)
Hepatic
All patients ALT Total 1707 1186
[ULN** 417 (24.4) 307 (25.9)
[3 9 ULN 44 (2.6) 31 (2.6)
[5 9 ULN 9 (0.5) 9 (0.8)
[10 9 ULN 4 (0.2) 2 (0.2)
Normal baseline ALT Total 1437 975
[ULN** 218 (15.2) 139 (14.3)
[3 9 ULN 12 (0.8) 2 (0.2)
[5 9 ULN 5 (0.3) 1 (0.1)
[10 9 ULN 3 (0.2) 0
Elevated baseline ALT Total 237 197
[ULN** 173 (73.0) 155 (78.7)
[3 9 ULN 30 (12.7) 28 (14.2)
[5 9 ULN 4 (1.7) 8 (4.1)
[10 9 ULN 1(0.4) 2 (1.0)
ALT alanine aminotransferase, LLN lower limit of normal, ULN upper limit of normal, WBC white blood
cell
* p = 0.001, ** p[ 0.05
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adverse event at an incidence of[0.2 %, providing reas-
surance that the data collected thus far will be useful in
informing the benefit/risk assessment of dalbavancin. Fur-
ther refinements of the safety profile will follow with the
addition of new clinical trial data and a rigorous post-
marketing surveillance program.
The rate of adverse events for patients treated with
dalbavancin was similar or slightly lower relative to a pool
of comparator agents that included cephalosporins, van-
comycin, oxacillin, nafcillin, and linezolid, whether from
any cause or related to drug, based on the investigator’s
assessment of causality. The types of treatment-related
adverse events observed are those commonly seen in
patients enrolled in clinical trials, including nausea, diar-
rhea, and pruritus. While a reduction in adverse event rates
of 2–3 % may be of limited clinical significance to the
treatment decision for an individual patient, it may be more
meaningful on a population basis and, at a minimum,
provide some reassurance that dalbavancin is safe and well
tolerated relative to alternative treatment options.
One concern that could be raised regarding any drug
with a long half-life is that adverse events, when they
occur, could last longer, be more severe and possibly occur
later, than would occur with a drug with a short half-life.
However, patients treated with dalbavancin had a mean
duration of adverse events that was similar to that of the
much shorter-acting comparators, and these events did not
occur any later post-baseline than did events occurring with
the comparator, even though follow-up visits occurred up
to 70 days after the last scheduled visit.
No difference in the adverse event profile was seen
when patients were assessed by age, sex, or race. No dif-
ference was also seen in the rate of either renal- or hepatic-
associated adverse events. Fewer patients treated with
dalbavancin had an elevation in creatinine assessed either
against the pooled comparators or against vancomycin,
specifically. Similar numbers of patients had abnormalities
in hematologic indices.
Increases in serum levels of liver enzymes [ALT,
aspartate transaminase (AST)], associated with micro-
scopic findings (histiocytic vacuolation and focal hepato-
cyte necrosis) in the liver, were noted in toxicology studies
in rats and dogs when dalbavancin was administered daily
for 28–90 days. In addition, renal toxicity characterized by
increases in blood urea nitrogen (BUN) and creatinine and
microscopic kidney findings was observed in rats and dogs
at doses 5–7 times higher than the expected human dose on
an exposure basis. In the clinical program, the majority of
the patients with elevated transaminases were found to
have other underlying conditions associated with a higher
likelihood of hepatic transaminase elevations, even with a
normal ALT at baseline, and, overall, they occurred at
similar rates with dalbavancin and the comparator.
Our analyses have some limitations. Presentations of
pooled safety data prior to marketing authorization are only
the first step in the collection of important safety information.
Safety data collected from the post-marketing experience
will ultimately contribute significantly to our understanding
of safety and tolerability, both because the drug is now used
in more typical and less controlled circumstances than seen
Table 9 Summary of total adverse events for patients receiving[10 days of active or placebo intravenous dosing in DISCOVER
Number of patients who experienced at least one Dalbavancin (N = 61) Vancomycin (N = 54) p value
TEAE 18 (29.5) 25 (46.3) 0.08
TEAE leading to premature discontinuation of study drug 1 (1.6) 0 1.0
Drug-related TEAE 3 (4.9) 3 (5.6) 1.00
Serious TEAE 1 (1.6) 7 (13.0) 0.03
Serious TEAE leading to premature study drug discontinuation 0 0 1.0
Drug-related serious TEAE 0 0 1.0
Serious TEAE leading to death 0 1 (1.9) 0.23
Nephrotoxicity on therapya
Safety population 21/637 (3.3) 31/638 (4.9) 0.16
All dalbavancin patients versus IV vancomycin only 21/637 (3.3) 5/54 (9.3) 0.06
Patients who received only IV therapy and no oral therapyb 1/58 (1.7) 5/54 (9.3) 0.21
Data are presented as n (%) unless otherwise indicated
IV intravenous, TEAE treatment-emergent adverse event
a Nephrotoxicity defined as a 50 % increase from baseline serum creatinine or an absolute increase in serum creatinine of 0.5 mg/dl; p value by
Fischer’s exact test
b Dalbavancin-active (and IV vancomycin-placebo) versus IV vancomycin-active (and dalbavancin-placebo) without receiving oral
linezolid/placebo
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in a clinical trial and because the number of patients
exposed to the drug will increase dramatically. It should be
noted that one phase II study and one phase III study have
not been previously published but are included in the safety
assessments for completeness; both studies were performed
in patients with skin infections, and the safety outcomes
within each trial were similar to the overall experience
(Data on file, Allergan plc.). The presentation of these
safety data could have been alternatively displayed as rel-
ative risk with controls for heterogeneity, given that the
patients were enrolled in many studies, not one large trial.
However, ultimately, given that the patients were selected
for entry into the studieswithmany criteria common to each
trial, data were collected via a standardized data-collection
instrument and statistical analyses performed through one
set of programs, the overall interpretation of outcomes
would not be materially different if analyzed with a dif-
ferent approach. Lastly, it should also be pointed out that
approximately 20 % of patients in this pooled analysis had
an uncomplicated skin infection and received a single dose
of dalbavancin 1000 mg. Though they did not receive a
total dose of dalbavancin 1500 mg, they had a significant
duration of exposure to drug over the observation period
given the compound’s long half-life, and including the
outcomes from these patients provides greater precision for
our estimates of any late adverse sequelae.
5 Conclusion
Relative to other options for treatment of Gram-positive
infections of the skin, dalbavancin was safe and well tol-
erated in an extensive clinical trial database of patients
with skin and skin structure infection. Collection and
analysis of post-marketing surveillance data will help fur-
ther refine this favorable overall safety profile.
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